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peptidomics has been applied to
the saliva of patients with oral
squamous cell carcinoma,
enabling the discovery of
signatures correlated with poor
prognostic factors, including
lymph-node metastasis. Sequence
analysis of differential peptides
allowed the prediction of proteases
implicated in endogenous
proteolysis and associated with
prognosis in head and neck
cancers. The results of combined
saliva peptidomics and proteomics
revealed that the accentuated
proteolysis in patients with oral
squamous cell carcinoma and
lymph-node metastasis concurs
with reduced levels of protease
inhibitors in saliva.
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RESEARCHPeptidomics-Driven Strategy Reveals Peptides
and Predicted Proteases Associated With Oral
Cancer Prognosis
Leandro Xavier Neves1 , Daniela C. Granato1, Ariane Fidelis Busso-Lopes1,
Carolina M. Carnielli1, Fábio M. de Sá Patroni2, Tatiane De Rossi1, Ana Karina Oliveira1,
Ana Carolina P. Ribeiro3, Thais Bianca Brandão3, André Nimtz Rodrigues4,
Pammela Araujo Lacerda5, Miyuki Uno6, Nilva K. Cervigne5, Alan Roger Santos-Silva7,
Luiz Paulo Kowalski8, Marcio Ajudarte Lopes7, and Adriana F. Paes Leme1,*Protease activity has been associated with pathological
processes that can lead to cancer development and pro-
gression. However, understanding the pathological un-
balance in proteolysis is challenging because changes can
occur simultaneously at protease, their inhibitor, and
substrate levels. Here, we present a pipeline that com-
bines peptidomics, proteomics, and peptidase predictions
for studying proteolytic events in the saliva of 79 patients
and their association with oral squamous cell carcinoma
(OSCC) prognosis. Our findings revealed differences in the
saliva peptidome of patients with (pN+) or without (pN0)
lymph-node metastasis and delivered a panel of ten
endogenous peptides correlated with poor prognostic
factors plus five molecules able to classify pN0 and pN+
patients (area under the receiver operating characteristic
curve > 0.85). In addition, endopeptidases and exo-
peptidases putatively implicated in the processing of dif-
ferential peptides were investigated using cancer tissue
gene expression data from public repositories, reinforcing
their association with poorer survival rates and prognosis
in oral cancer. The dynamics of the OSCC-related prote-
olysis were further explored via the proteomic profiling
of saliva. This revealed that peptidase/endopeptidase
inhibitors exhibited reduced levels in the saliva of pN+
patients, as confirmed by selected reaction monitoring–
mass spectrometry, while minor changes were detected
in the level of saliva proteases. Taken together, our results
indicated that proteolytic activity is accentuated in the
saliva of patients with OSCC and lymph-node metastasis
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This is an open access article under the CC BY license (http://creativecommons.org/licesalivary peptidase inhibitors. Therefore, this integrated
pipeline provided better comprehension and discovery of
molecular features with implications in the oral cancer
metastasis prognosis.
Proteolysis is an irreversible protein modification involved in
different cellular processes under physiological conditions (1).
However, increased proteolytic activity is implicated in
numerous diseases including cancer pathogenesis, as
demonstrated by the prominent role of proteases in tumor
growth, angiogenesis, invasion, and metastasis (2). Conse-
quently, proteases have been investigated for diagnosis,
prognosis, and therapeutic purposes in cancer (3–5).
Proteomic technologies have been shown to be useful to
uncover molecular changes in protein or peptide abundances
that may assist cancer diagnosis and prognosis by providing
information that cannot be assessed by the routine clinical
evaluation (6, 7). Noteworthy, peptidomic methods can com-
plement the results from conventional bottom-up proteomics
by providing insights on relevant proteolytic events (8) often
lost during in vitro trypsin digestion. Therefore, the analysis of
endogenous peptides from saliva may provide a new layer of
information useful in the discovery of oral squamous cell
carcinoma (OSCC) prognostic markers.
Peptidome analysis by liquid chromatography–tandem
mass spectrometry (LC-MS/MS) can be challenging because
of nonspecific protease digestion during sample preparation
and computational processing of data, as well as difficulties infor Research in Energy and Materials, Campinas, Brazil; 2Molecular
pinas, Brazil; 3Dental Oncology Service, São Paulo Cancer Institute,
Medicine of Jundiaí, Jundiaí, Brazil; 5Department of Internal Medicine,
undiaí, Jundiaí, Brazil; 6Center for Translational Research in Oncology,
ent, Piracicaba Dental School, University of Campinas, Piracicaba, São
y of São Paulo, São Paulo, Brazil
npem.br.
iências, LNBio, Centro Nacional de Pesquisa em Energia e Materiais –
Mol Cell Proteomics (2021) 20 100004 1
chemistry and Molecular Biology.
nses/by/4.0/). https://doi.org/10.1074/mcp.RA120.002227
Salivary Peptidome Correlates With Oral Cancer Prognosisthe biological interpretation (9). Among the methods that have
emerged, the terminal amine isotopic labeling of substrates
can be highlighted as a strategy that allows mapping in vivo
processing of protein termini (10). Alternatively, the develop-
ment of robust in silico analysis tools has also permitted the
reconstruction of cleavage sites to predict active peptidases
according to their known specificity or peptide libraries
(11, 12). Thereby, the identification and analysis of endoge-
nous peptides from complex biological samples such as liquid
biopsies (e.g., plasma/serum, urine, and saliva) has proved to
be feasible (13, 14).
Therefore, considering the need for molecular markers to
assist OSCC prognosis and the relevance of proteolytic pro-
cess in cancer progression, we developed a simple and robust
pipeline to analyze endogenous peptides and proteins from
the saliva of patients with oral cancer. From mass spectrom-
etry data, a sequential computational framework was estab-
lished enabling cleavage site analysis, prediction of proteases,
and correlation of their gene expression levels with OSCC
prognosis using The Cancer Genome Atlas (TCGA) cancer
database. Peptidome and proteome profiling uncovered
subsets of molecules correlated with prognostic factors and
was able to distinguish patients with and without lymph node
metastasis. Thereby, our approach delivered a multifaceted
view of proteolytic events taking place in the oral cavity of
patients with OSCC with prognostic utility.EXPERIMENTAL PROCEDURES
Experimental Design and Statistical Rationale
A total of 79 saliva samples collected from patients with OSCC
before any therapeutic intervention were used in this discovery study.
Samples were divided into two groups of individuals diagnosed with
(N+, n = 44) or without (N0, n = 35) cervical lymph node metastasis, a
feature with major relevance in OSCC prognosis. Twenty-five samples
were analyzed via peptidomics (cohort 1, pN0, n = 12; pN+, n = 13), 14
via bottom-up proteomics (cohort 2, pN0, n = 9 and pN+, n = 5), and
40 (cohort 3, N0, n = 14 and N+, n = 26) via Tier 2 exploratory targeted
analysis (selected reaction monitoring–mass spectrometry [SRM-
MS]), according to the availability of samples in our biorepository. All
patients from cohorts 1 and 2 had pathological confirmation of lymph
node metastasis, whereas classification of cohort 3 was predomi-
nantly clinical. In the discovery phases—that is, peptidomics, cohort 1,
and bottom-up proteomics, cohort 2—samples were analyzed as
single replicates, and a two-group comparison (pN0 versus pN+) was
performed by Perseus, v1.6.10.45, using ANOVA (α = 0.05). Multiple
comparison corrections were not applied at this stage because the
consistency of observed differences was also evaluated through
correlation analysis and receiver operating characteristic (ROC) curves
(using R environment) or SRM-MS assay. Correlation analysis was
performed to evaluate associations between the levels of endogenous
peptides and proteins with anatomopathological data with prognostic
utility. In addition, ROC curves were used to investigate proteins or
peptides with acceptable power to discriminate pN0 and pN+ pa-
tients; area under the receiver operating characteristic curve (ROC-
AUC) threshold was set to 0.7 in accordance with Hosmer Jr et al. (15).
For SRM-based result verification, 40 samples (cohort 3) were
analyzed as three technical replicates. The abundance of targets was2 Mol Cell Proteomics (2021) 20 100004normalized by internal standard spikes of stable labeled synthetic
peptides and then compared between N0 and N+ groups using nested
ANOVA (α = 0.05)—to account for technical and biological variations—
and the Mann–Whitney test (α = 0.05)—for comparison of group av-
erages. Patients' clinical information is available in supplemental
Table S1. Run order was randomized using R (v3.4.0) environment
to prevent systematic bias during MS acquisition (supplemental
Table S2). Two patients with tumor recurrence and lymphoma were
not considered in the final analysis of peptidomics data (i.e., cohort 1;
supplemental Table S3).
Saliva Collection
Clinical samples were provided by Biobanco-Rede Premium, Fac-
uldade de Medicina/Instituto de Câncer do Estado de São Paulo
(cohorts 1 and 3), Faculdade de Medicina de Jundiai (cohort 2), and
Faculdade de Odontologia de Piracicaba (cohorts 1 and 3). All pro-
cedures presented in this study were performed in accordance with
the approved guidelines, patient informed consent, and institutional
research ethics committees through Plataforma Brasil Certificado de
Apresentação de Apreciação Ética #61402116.8.0000.0065 and
#30658014.1.1001.0065 (Instituto de Câncer do Estado de São
Paulo), #45091715.1.0000.5412 (Faculdade de Medicina de Jundiai),
and #1.175.243 (Faculdade de Odontologia de Piracicaba). Saliva was
collected during the morning period from individuals who had not
eaten or ingested liquids (except for water) and had not performed oral
hygiene for at least the past 1 h. Donor individuals were first instructed
to perform a mouth wash with 5 ml of water, and saliva was collected
without stimulation in a 15-ml falcon tube, according to a previously
published protocol (16). Saliva aliquots were stored at −80 ◦C.
Preparation of Saliva for Peptidomics
One milliliter of saliva was centrifuged at 500g for 10 min, 4 ◦C, to
sediment cells and then the supernatant diluted to 30 ml in ice-cold
PBS, pH 7.4, containing 1-mM PMSF and 5-mM EDTA. Ultracentri-
fugation at 110,000g, 4 ◦C, was performed for 1 h for recovery of
supernatants comprising the saliva soluble fraction. Two methods for
peptide extraction were evaluated using a test sample before pro-
cessing the patients' saliva. In the first protocol (hydrochloric acid
saliva treatment followed by solid-phase extraction of peptides [HCl-
SPE]), samples were acidified with HCl to pH 2 (approximately 40-
mM final concentration), after centrifugation at 12,800g, for 20 min,
at 4 ◦C. The supernatant was recovered and peptides purified by
solid-phase extraction (Sep-Pak C18, 500 mg; Waters), as described
elsewhere (17). The eluted peptides were dried in SpeedVac (Thermo
Scientific) and desalted using StageTips C18 (18). The second method
was based on the enrichment of the peptidome by ultrafiltration (ul-
trafiltration of saliva followed by solid-phase extraction of peptides
[UF-SPE]) upon a 3-kDa cutoff. First, urea and DTT were added to the
samples at the final concentrations of 4 M and 10 mM, respectively.
After centrifugation at 12,800g, for 20 min, at 4 ◦C, the clarified su-
pernatant was transferred to Amicon Ultra-15 molecular weight cut-off
3-kDa tubes (Merck Millipore), to proceed with filtration at 4000g, at
4 ◦C, for approximately 90 min. The filtered solution enriched with the
low-molecular-weight proteome was acidified with TFA to 0.5% final
concentration (pH ~2) and then submitted to solid-phase extraction by
C18-reversed phase chromatography (Sep-Pak C18, 500 mg; Waters),
as performed previously and then vacuum dried. Peptides were sol-
ubilized in 0.1% formic acid, and the final yield of the recovered
peptides was assessed using the Quantitative Colorimetric Peptide
Assay (Thermo Scientific). The method with best performance in terms
of the number of peptide-spectrum match, unique sequences, and
proteins identified was used to prepare the saliva samples obtained
from patients with oral cancer. Extraction methods were compared
Salivary Peptidome Correlates With Oral Cancer Prognosisunder optimized LC-MS/MS configuration detailed in the following
sections.
Preparation of Saliva for Bottom-Up Proteomics and SRM-MS
Saliva was centrifuged for 5 min at 1500g, 4 ◦C, to pellet intact cells
and debris. The protein concentration was determined on the super-
natant using the Bradford assay kit (Bio-Rad). An aliquot with 10 μg of
total protein was digested in the solution using trypsin, essentially as
described elsewhere (19). In brief, samples were treated with urea
buffer (100-mM Tris-HCl, pH 7.5, 8-M urea, 2-M thiourea, 5-mM
EDTA, 1-mM PMSF, and 1-mM DTT) containing cOmplete Mini Pro-
tease Inhibitor Cocktail (Roche) and the mixture sonicated in an ul-
trasound bath for 10 min. After centrifugation at 10,000g for 5 min, the
supernatants were sequentially treated with 5-mM DTT (for 25 min, at
56 ◦C) and 14-mM iodoacetamide (for 30 min in the dark, at RT) for
protein reduction and alkylation of cysteines. The mixture was then
diluted with 50-mM ammonium bicarbonate to lower urea concen-
tration to 1.6 M and calcium chloride added to 1-mM final concen-
tration. Samples were digested for 16 h at 37 ◦C using sequencing
grade-modified trypsin (Promega) at a 1:50 enzyme-to-protein ratio.
After overnight incubation, more trypsin (1:50) was added to samples
prepared for bottom-up analysis, and digestion was continued for 5 to
6 h. The reaction was terminated by acidification to 0.4% TFA. Pep-
tides were desalted with StageTips C18 (3 M Empore), dried in a
vacuum concentrator, and reconstituted in 0.1% formic acid.
LC-MS/MS Analysis for Peptidomics and Bottom-Up Proteomics
Tryptic and endogenous saliva peptides were analyzed using the
EASY-nLC II (Proxeon Biosystems) coupled to the LTQ-Orbitrap Velos
mass spectrometer (Thermo Fisher Scientific). Approximately 750 ng
or 2 μg of peptides, for peptidomics or proteomics, respectively, were
resolved by reversed-phase chromatography using the analytical
column PicoFrit C18 (20 cm × 75 μm id, 5 μm; New Objective) at a
constant flow rate of 300 nl/min. For peptidomics, a round of gradient
optimization was performed using the following ramps of phases A
(0.1% formic acid in water) and B (0.1% formic acid in acetonitrile
[MeCN]): method 1 (M1), 10 to 30% B over 27 min and then 30 to 45%
B in 5 min; method 2 (M2) 2 to 20% B over 25 min and then 20 to 30%
B in 7 min; method 3 (M3) 2 to 30% B over 27 min and then 30 to 45%
in 5 min. All ramp configurations were followed by identical washing
and conditioning steps. For proteomics, tryptic digests were resolved
over a 212-min gradient (2–90% B; 35% B at 175 min). Eluting pep-
tides were analyzed by the mass spectrometer operating in a positive
mode. Data-dependent acquisition of saliva peptidome and tryptic
digest was performed using similar parameters, except for the mini-
mum charge state of peptides selected for MS/MS analysis, +1 or +2,
for endogenous or tryptic peptides, respectively. In both approaches,
precursor ions (m/z 300–1600) were scanned in the Orbitrap with
resolution defined to r = 60,000 and 1E6 target ions. Up to 20 most
intense ions (5E4 target ions) were isolated through a 3-Da window
and activated by collision-induced dissociation, with normalized
collision energy of 35%, activation Q = 0.25, and activation time of
10 ms. Product ions were detected by the ion trap operating in the
normal scan rate. Dynamic exclusion was enabled with an exclusion
list of up to 500 ions, an exclusion duration of 60 s, and a count
repetition of 1.
Processing of Peptidomics Data
De novo sequencing–assisted database searching (20) was per-
formed using PEAKS Studio X (Bioinformatics Solutions Inc). Search
parameters included unspecific proteolysis, enabling peptides with up
to 65 residues to be matched, and mass error tolerance of 10 ppm
and 1 Da for precursor and product ions, respectively. Oxidation ofmethionine residues (+15.99 Da) and acetylation of proteins N-termini
(+42.01 Da) were allowed as variable modifications. Peptide se-
quences matching the Human UniProt database (93,599 protein se-
quences, 36,574,184 residues, release June 2018) were obtained at
a false discovery rate (FDR) ≤ 0.01 for both proteins and peptides.
FDR estimates were calculated using the “decoy-fusion” method built
in the PEAKS Studio software (20). Quantitative data were generated
by the PEAKS Q module using normalized precursor intensity
extracted using a 10-ppm tolerance and a 2-min retention time win-
dow. PEAKS Q quality threshold was adjusted to 8 to remove lower-
quality quantitative features, and only peptides with at least one valid
value in both pN0 and pN+ groups were considered for relative
quantification.
Processing Bottom-Up Proteomics Data
Raw data were processed using MaxQuant v1.5.8.0 software
(https://www.maxquant.org/), and MS/MS spectra were searched
against The Human UniProt database (93,599 protein sequences,
36,574,184 residues, release June 2018) using the Andromeda search
engine. Search parameters included tolerance of 6 ppm for precursor
ions and 0.5-Da for product ions, trypsin/P enzyme specificity with a
maximum of two missed cleavages. Carbamidomethylation of
cysteine (+57.02) was considered a fixed modification, and oxidation
of methionine (+15.99) and protein N-terminal acetylation (+42.01)
were considered variable modifications. The FDR was estimated using
the target-decoy method (21) and set to ≤0.01 for both the protein and
peptide matches. Protein quantification was performed using the LFQ
algorithm implemented in MaxQuant software, with a minimal ratio
count of one and a 2-min window for matching between runs. Iden-
tified protein entries were processed excluding reverse sequences
and those identified “only by site.”
Association of Peptide and Protein Abundances With Clinical Data
Linear regression analysis was performed using the R (v3.6.0)
environment to evaluate the relationship between endogenous pep-
tide and protein abundances with clinicopathological features,
namely, the size of tumor, pathologically confirmed presence and
stage of lymph nodal metastasis (pN), differentiation, extracapsular
extension, worse pattern of invasion, perineural invasion, and blood/
lymphatic vessel invasion. Linear regression with p-value ≤ 0.05 was
used to define significance. The Pearson product–moment correlation
coefficient (denoted by R) was also calculated to measure the strength
of the association between protein and peptide abundances and
clinicopathological features. Peptides with R < −0.7 or 0.7 < R, R2 >
0.5, at least 6 valid values per group, and ≥3 valid values per clinical
feature were considered.
ROC Curve by Logistic Regression and Random Forest Analysis
The power of each endogenous peptides and proteins as classifiers
to discriminate pN0 and pN+ patients was evaluated by the con-
struction of ROC curves using random forest (22) and logistic
regression. Binary regression was used when multiple peptides were
combined. The sensitivity and specificity were calculated using the
peptide or protein intensities from label-free quantification experi-
ments. The area under the curve (AUC-ROC) with a 95% confidence
interval was used for comparison. Optimal cut-off by highest sensi-
tivity (true-positive rate) in function of the specificity (false-positive
rate) was calculated, and the decision threshold was assigned to the
value of 70%. For all statistical comparisons, an ANOVA p-value ≤
0.05 was used to define significance. The data analysis was per-
formed using the package pROC (23) and the R environment, version
3.4.4.Mol Cell Proteomics (2021) 20 100004 3
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Prediction
Differentially abundant peptides had their N- and C-terminal flank-
ing residues mapped on full-length protein sequences (UniProt Human
proteome, release June 2018) using DBToolKit, v4.2.4 (24) to recon-
struct the cleavage sites. Amino acid frequency (P3-P3ʹ) was deter-
mined by IceLogo v1.0.2 (https://iomics.ugent.be/icelogoserver/)
compared with natural occurrence in the human proteins deposited at
SwissProt database. Over-representation of amino acids was
considered when p-value was ≤0.05.
Protease prediction was carried out by Proteasix (http://proteasix.
org/) tool (11) from the same subset of differential saliva peptides
using the “observed” mode, that is, matching against cleavage site
associations collected from the literature.
Biological Characterization and Search for Hub Molecules
Proteases predicted to cleave the differential peptides (pN0 versus
pN+) were submitted to over-representation test of Gene Ontology
(GO) annotation of biological processes, molecular functions, and
cellular component using DAVID (25). An interaction network (p-value
< 0.05) was created using Contextual Hub Analysis Tool against
Reactome database in Cytoscape 3.4.0 (26).
Association of Predicted Proteases With Prognosis Using
Database Repositories
The association of transcript levels of predicted proteases in the
tissues of patients with a prognosis of oral cancer was evaluated using
PROGgene v2 tool (27). This analysis was performed with the list of
proteases predicted to cleave peptides differentially abundant be-
tween pN0 and pN+ patients. PROGgene generated survival curves
considering the gene expression values from distinct databases
available for head and neck tumors. More specifically, four databases
were used to conduct the analysis, namely, TCGA (2015), GSE65858
(28), GSE27020 (29), and E-MTAB-1328 (30), providing clinical and
molecular information from 291, 269, 108, and 89 patients with head
and neck cancer, respectively. Median gene expression was used as a
cut-off to determine low and high expression of selected markers, and
significance threshold was set to p-value ≤ 0.05.
A survival analysis was also performed using Kaplan–Meier curves
and the log-rank test. In the univariate survival analysis, the compar-
ison was performed between the higher and the lower expression
values. These were defined by group formation considering the log2
expression of the protease of interest in patients assessed from the
TCGA database. Unbiased group assignment was achieved using
mclust package (31) under R environment. For the multivariate survival
analysis, the Cox proportional hazard model with a stepwise method
was used. A p-value < 0.05 was set as the significance threshold in the
Cox proportional hazard model (32). Data were tested for normality
and homogeneity of variance using the Shapiro–Wilk test (p-value ≤
0.05) to drive decisions of parametric or nonparametric tests for group
comparison with the clinical categories.
Development and Analytical Validation Targeted MS Assay
Proteotypic peptides of alpha-2-HS-glycoprotein (AHSG; fetuin A)
and serine protease inhibitor Kazal-type 5 (SPINK5) were selected
according to Gallien et al. and Lange et al. (33, 34). In brief, sequences
unique to AHSG and SPINK5 protein products, fully tryptic (P1 = K/R),
and <20 amino acids residues were selected from the peptide list
provided by shotgun proteomics. Based on these criteria, two
peptides (FSVVYAK and HTLNQIDEVK) were selected for fetuin
A while seven candidates remained available for SPINK5. In that
case, the list of SPINK5 peptide candidates was narrowed to a subset
of three sequences (FFQSLDGIMFINK, ATAPTELNCDDFK, and4 Mol Cell Proteomics (2021) 20 100004EAVQELCSEYR) that also presented empirical evidence in our previ-
ous shotgun analysis OSCC saliva (16) and SRMatlas repository
(http://www.srmatlas.org).
Relative quantification of fetuin A and SPINK5 across 40 OSCC
saliva samples (cohort 3) was carried out in the presence of 0.8-5
pmol/ul surrogate stable isotope labeled peptides (Thermo Scientific)




nine. In addition to fetuin A and SPINK5 surrogate peptides, samples
were also spiked with the Pierce Retention Time Calibration Mixture
(120 fmol on column; Thermo Scientific) for monitoring instrument
stability during SRM-MS acquisition. Two SPINK5 surrogate peptides
(ATAPTELNCDDFK and EAVQELCSEYR) were not detected during
SRM assay development, thus were not included in the final analysis
of cohort 3. The other target analytes were monitored using three
transitions in the light and heavy channels (AHSG protein: FSVVYAK,
m/z 407.22, +2, and [y3] m/z 381.21+, [y4] m/z 480.28+, [y5] m/z
579.35+; HTLNQIDEVK,m/z 598.82, +2, and [y2]m/z 246.18+, [y4]m/z
490.25+, [y5] m/z 603.33+; and SPINK5 protein: FFQSLDGIMFINK, m/
z 780.40, +2 and [y2]m/z 261.15+, [y4]m/z 521.31+, [y5]m/z 652.35+).
Transition selection was based on the ranking order provided by
Skyline using data-dependent acquisition spectra.
Samples were analyzed on a Xevo TQ-XS triple quadrupole mass
spectrometer (Waters), as described by Carnielli et al. (18). One
microgram of saliva digest was resolved over a 60-min gradient using
an Acquity UPLC-Class M equipped with a trap column (Waters
Acquity UPLC BEH C18 130A, 5 μm, 300 μm × 50 mm) and a BEH
Shield C18 IonKey column (10-cm × 150-μm ID packed with 1.7-μm
C18 particles, Waters) at 1.2 μl/min flow rate and temperature set to 40
◦C. MeCN gradient started at 2% B (MeCN, 0.1% formic acid),
following a linear ramp to 40% B over 45 min, followed by a step in-
crease to 85% B until 47 min and conditioning at 2% B until 60 min.
Mass spectrometry analysis of eluting peptides was performed via
SRM-MS, with quadrupoles Q1 and Q3 operating as unit mass res-
olution (0.7 Th full width at half maximum). Schedule SRM acquisition
was adjusted to a 3-min elution window, with dwell times automati-
cally set in MassLynx v4.2 to achieve at least ten points per peak over
a 15-s elution profile. The optimal collision energy was determined for
each peptide by Skyline. To avoid systematic bias in data acquisition,
samples were randomized using the software R v3.4.0 (35) and
analyzed in triplicate. A sample order in each replicate batch was
randomized independently. The data analysis was manually performed
in Skyline v20.1.0.76.RESULTS
Development of an Analytical Pipeline for the Study of the
Salivary Peptidome
Before the analysis of samples from patients with OSCC, we
evaluated the performance of two extraction methods (HCl-
SPE and UF-SPE) and three liquid chromatographic condi-
tions (M1, M2, M3) to achieve improved coverage of the saliva
peptidome (Fig. 1). The extraction methods explored physical-
chemical features such as isoelectric precipitation, hydro-
phobicity, and molecular mass to separate endogenous
peptides from intact soluble proteins. The first protocol (HCl-
SPE) consisted of the direct loading of diluted and acidified
saliva samples (pH ~2) onto solid-phase C18 cartridges for
peptide binding, whereas the second approach (UF-SPE) was
based on centrifugal ultrafiltration followed by solid-phase
extraction. Test samples were then evaluated using three
LC-MS methods, varying on MeCN ramp configuration, to
FIG. 1. Pipeline for characterization of saliva peptidome and proteome. A pool of saliva (n = 3) was first used to optimize the methodology
for peptide recovery and analysis via LC-MS/MS. Briefly, peptide fractions were recovered by (i) saliva acidification with HCl (pH 2) followed by
C18 solid-phase extraction (HCl-SPE) or (ii) 3-kDa ultrafiltration under denaturing conditions (4 M urea, 10-mM DTT) followed by C18 solid-phase
extraction (UF-SPE) of the flow through. LC-MS/MS analysis of HCl-SPE and UF-SPE was performed by testing three variations of a 45-min
acetonitrile gradient (M1, M2, and M3) for improved peptide separation. Saliva from patients with oral squamous carcinoma (OSCC) and with
and without lymph-node metastasis pathologically confirmed, pN0 and pN+, respectively, were prepared using the HCl-SPE protocol. Tandem
spectrum data acquired using an LTQ-Orbitrap Velos operating in Top20 DDA mode using CID activation were processed in PEAKS Studio X—
using an unspecific digest mode—or MaxQuant, for peptidomic and proteomics analyses, respectively. Differential molecules between pN0
versus 'pN+ group comparison were submitted to correlation tests with prognostic factors, such as invasiveness, differentiation, and extrac-
apsular extension. Differential protein and peptides were also tested as classifiers of pN0 and pN+ patients using ROC curves. Cleavage site
analysis revealed potential proteases implicated in the breakdown of saliva proteins and correlated with prognosis. Complementary proteomics
analysis uncovered regulatory mechanisms of saliva proteolysis via peptidase, enzymes, and inhibitors levels, finally verified via SRM-MS. DDA,
data-dependent acquisition; GO, Gene Ontology; HCl-SPE, hydrochloric acid saliva treatment followed by solid-phase extraction of peptides;
LC-MS/MS, liquid chromatography–tandem mass spectrometry; ROC, receiver operating characteristic; SRM-MS, selected reaction
monitoring–mass spectrometry; UF-SPE, ultrafiltration of saliva followed by solid-phase extraction of peptides.
Salivary Peptidome Correlates With Oral Cancer Prognosisprovide improved chromatographic conditions for peptide
identification.
Mass spectrometry analysis of the saliva peptidome resul-
ted in the identification of peptides with ion intensities span-
ning over six orders of magnitude, regardless of the extraction
methods or LC-MS gradient (Fig. 2, A–B). Under similar
sample loads, the average number of peptides identified using
HCl-SPE extraction (667 sequences) was 1.8× higher than the
average observed in UF-SPE (367 sequences, Fig. 2, A–B;
supplemental Tables S4 and S5). The HCl-SPE procedure also
delivered more peptide-spectrum match (1.8× increase, 593
versus 1049) and unique peptides (2.7× increase, 149 versus398; Fig. 2B). Notably, the increase in the number of proteins
identified using HCl-SPE protocols was less pronounced
(1.2×) compared with the other metrics, but the superior
average ratio of unique peptides per protein exhibited in
comparison to UF-SPE (7 versus 3) indicated a higher
coverage of cleavage products per protein.
Peptide length analysis indicated that ultrafiltration clearly
limited the size of peptides recovered, biasing the analysis to a
subset of polypeptides containing no more than 27 to 30
amino acid residues (Fig. 2C). The distribution of grand
average of hydropathy values across the methods shows that
the extraction method used had minor influence on theMol Cell Proteomics (2021) 20 100004 5
FIG. 2. Optimization of the saliva peptidome extraction and LC-MS/MS analysis. Endogenous peptides recovered from saliva using either
ultrafiltration (3-kDa MWCO; UF-SPE) or HCl acidification following C18 solid-phase extraction (HCl-SPE) were analyzed using three LC gradients
(M1, M2, and M3) to achieve optimal chromatographic separation. A, samples prepared with the HCl-SPE extraction method had higher
identification rates, particularly when the gradient M2 was used for resolving the peptidome. B, abundant range of peptides detected spanned
over 5 to 6 orders of magnitude. C, the ultrafiltration-based method biased the analysis toward endogenous peptides <3 kDa while HCl-SPE
extraction allowed the recovery of larger peptides. D, GRAVY values of peptides identified across the experimental conditions suggested
that LC gradients played a major role in the identification of more hydrophobic peptides regardless of the extraction method used. Kruskal–
Wallis with Dunn's tests indicated significant differences; *p-value < 0.05, ****p-value < 0.0001. Box plot boundaries at 10th and 90th
percentiles. GRAVY, grand average of hydropathy; HCl-SPE, hydrochloric acid saliva treatment followed by solid-phase extraction of peptides;
LC-MS/MS, liquid chromatography–tandem mass spectrometry; MWCO, molecular weight cut-off; UF-SPE, ultrafiltration of saliva followed by
solid-phase extraction of peptides.
Salivary Peptidome Correlates With Oral Cancer Prognosishydrophobicity of peptides identified, unlike the chromato-
graphic settings tested (Fig. 2D). Overall, the combination of
HCl-SPE sample preparation strategy and the LC condition
“M2” outperformed the other methodologies so that HCl-
SPE_M2 was the method of choice for clinical samples
analysis.
Patients With OSCC and Nodal Metastasis Exhibit a
Distinctive Salivary Peptidome
The successful development of a protocol suitable for saliva
peptidome extraction and MS analysis allowed us to investi-
gate peptides potentially associated with oral cancer prog-
nostic factors such as lymph-node metastasis. For this
purpose, the saliva peptidome from 25 patients with OSCC
and with (pN+, n = 13) or without (pN0, n = 12) lymph-node
metastasis was first characterized using mass spectrometry6 Mol Cell Proteomics (2021) 20 100004and then following a pipeline of bioinformatic analyses (Fig. 1).
This included the prediction of proteases potentially associ-
ated with the generation of differential peptides between pN0
and pN+ saliva, and correlation analysis between prognostic
features and peptide abundance. Moreover, the association
between transcript levels of predicted proteases in tumor
tissues and prognosis of patients with head and neck cancer
was evaluated using PROGgene and data available in the
TCGA repository.
Of 4349 peptides identified in our data set (FDR ≤ 0.01;
supplemental Table S6), 1720 and 1001 peptides were
exclusive to pN+ and pN0 groups, respectively, while 1628
peptides were shared between the groups (Fig. 3A). Pearson
correlation coefficients of the 25 LC-MS/MS runs ranged from
0.5 to 0.9, anticipating a dynamic salivary peptidome (Fig. 3B).
After filtering lower-quality features in PEAKS Q (quality
FIG. 3. Composition analysis of the saliva peptidome from pN0 and pN+ OSCC patients. A, qualitative analysis reveals a significant
number of group-specific peptide matches and <40% overlap between pN0 and pN+ patients. B, the correlogram of the 25 LC-MS runs saliva
peptidome showing Pearson's R ranging from 0.5 to 0.9. C, the heat map of the whole saliva peptidomes and (D) differentially abundant peptides
(ANOVA p-value ≤ 0.05) show no clear grouping of samples based on a single classifier feature such as lymph node metastasis (N+/N0). Hi-
erarchical clustering was performed using the Pearson's correlation and Ward's method. E, differential distribution of peptides quantified in pN0
and pN+ samples represented on a volcano plot. Peptides above the significance threshold (ANOVA p-value ≤ 0.05) are highlighted as red dots.
Salivary Peptidome Correlates With Oral Cancer Prognosisthreshold = 8 and at least one valid value in both groups),
label-free quantitative data of 676 peptides—mapping to 48
protein groups—were used to assess differences between
pN0 and pN+ saliva (Fig. 3C). A subset of 77 peptides,assigned to 22 protein groups, was revealed to be differen-
tially abundant (ANOVA p-value ≤ 0.05) in the saliva of pa-
tients diagnosed with lymph node metastasis (Fig. 3, D–E,
supplemental Table S7). Despite group differences in peptideMol Cell Proteomics (2021) 20 100004 7
Salivary Peptidome Correlates With Oral Cancer Prognosisabundance, hierarchical clustered heat maps of both the
whole saliva peptidome and differential peptides did not
exhibit a clear separation toward pN+ and pN0 status.
Therefore, we evaluated whether other prognostic features
could be also associated with the differences observed in the
saliva peptidome.
Peptide Abundance in Saliva Correlates With
Clinicopathological Prognostic Factors
Quantitative data from the differential peptides (pN0 versus
pN+ comparison) were tested for association with patient's
clinicopathological information with prognostic value. Initially,
25 peptides, with ≥6 valid values (~50%) in either pN+ or pN0
two groups, presented significant association with prognostic
features when default statistical thresholds were used (linear
regression p-value < 0.05, and Pearson's R-squared > 0.5;
supplemental Table S8). By applying more stringent criteria
(≥3 valid values per clinical feature in addition to default
thresholds), a subset of ten endogenous peptides (Pep114,
Pep154, Pep167, Pep344, Pep366, Pep385, Pep529, Pep568,
Pep609, Pep670) correlated with extracapsular extension and
perineural invasion, in addition to lymph-node metastasis
(Fig. 4A; supplemental Table S8). Notably, all these peptides
exhibited higher abundance in pN+ saliva than in pN0.
Furthermore, correlation analyses pointed out that increased
levels were associated with worse prognostic factors, such as
the presence of perineural invasion or nodal metastasis.
Conversely, the occurrence of extracapsular extension in
lymph nodes—a feature presented only in pN+ patients—was
inversely proportional to Pep167 levels.
ROC curves were used to evaluate the power of differen-
tially abundant peptides to distinguish pN0 and pN+ patients
based on their quantitative profiles (supplemental Table S9).
Five peptides derived from basic salivary proline-rich proteins
(PRPs) (Pep631, Pep163, Pep361, Pep407, Pep626) were
consistently detected in at least 85% of the group samples
and exhibited an AUC-ROC higher than 70% in both random
forest and logistic regression analyses (Fig. 4B). Interestingly,
the power to classify pN0 and pN+ patients was increased to
an AUC of 86% when those five peptides were combined
(Fig. 4B), demonstrating that a molecular panel can perform
better in the classification of patients with nodal metastasis.
Cleavage Site Analysis Suggests Putative Proteases Are
Able to Modulate the Salivary Peptidome
Peptidases possibly implicated in the endogenous cleavage
of saliva proteins were predicted to provide a better under-
standing of the proteolytic events linked to the peptidome
changes observed between pN0 and pN+ samples. This was
achieved by reconstructing the putative cleavage sites
deriving three N- and C-terminal amino acid residues from the
full-length protein sequences (supplemental Table S10). A
graphical representation by the IceLogo and heat
map showed a significant over-representation of peptides8 Mol Cell Proteomics (2021) 20 100004produced upon N-terminal cleavage between Pro/Gln/Arg and
Gly/Ser, and C-terminal cleavage between Gln/Pro and Gly/
Arg residues (Fig. 5A, top sequence logo). Notably, the
enrichment of proline residues in the vicinity of the cleaved
peptide bonds was recurrent because sequences derived
from PRPs (UniProt IDs P04280, Q04118, P02812, P10163,
P02814) composed a major fraction of our peptide list. To
minimize this caveat, PRPs were filtered out and the data were
reanalyzed, revealing that preferential N-terminal cleavages of
non-PRPs happened between Phe and Val residues, while no
C-terminal cleavage site was found enriched (Fig. 5A; bottom
sequence logo).
Proteasix analysis has shown that 22 of the 77 differentially
abundant peptides are known substrates of up to 19 specific
endopeptidases and exopeptidases (supplemental Table S11)
that might be affecting the saliva peptidome in a disease-
specific manner. A heat map consolidating the abundance of
all peptides putatively produced by the predicted proteases
highlighted cathepsin K, L, and S; furin; and calpain 1 and 2 as
responsible for the cleavage of the most abundant peptides
(Fig. 5B). Overall abundance of substrates of each predicted
peptidase was similar between pN0 and pN+, with the
exception of peptides cleaved by cathepsin D, which pre-
sented higher intensities in N+ saliva (Fig. 5B).
GO enrichment analysis of the predicted proteases showed
the over-representation of cathepsins (CTS) with lysosomal
(CTSD, L, K, S) or vacuole (CTSE) origin (Fig. 6A). Together,
cathepsins L, K, and S; calpain 1 and 2; and caspase 6 exhibit
cysteine-type peptidase activity. Membrane metalloproteinase
2 and 25 were mostly involved in structural organization of the
extracellular matrix via proteolysis. Network analysis high-
lighted that predicted cathepsins and membrane metal-
loproteases are linked to immunity via Toll-like receptors and
antigen presentation (Fig. 6B).
Expression Patterns of Predicted Proteases Are Associated
With Cancer Prognosis
Because an association between differential peptides and
prognostic features was observed before, we also investi-
gated whether the expression levels of the predicted pro-
teases could be similarly associated with cancer prognosis
(supplemental Fig. S1). Publicly available PROGgene tool and
gene expression data from patients with head and neck car-
cinoma indicated that an augmented expression of CAPN1,
CAPN2, CTSB, and MMP11 genes in tumor tissue is associ-
ated with reduced overall survival (<40% in 5 years), while
reduced levels of MMP25 transcripts lower 5-year overall
survival. In addition, higher CAPN1 expression also correlates
with reduced metastasis-free survival, whereas relapse-free
survival is diminished when MMP25 and TMPRSS6 expres-
sion is decreased.
Transcript levels of the predicted proteases could also be
associated with specific prognostic features such as the tu-
mor size, recurrence, invasiveness, nodal metastasis, and
FIG. 4. Correlation of differential peptides with OSCC prognostic factors. A, ten differentially abundant peptides, with increased levels in
pN+ saliva, were correlated with prognostic features such as perineural invasion, nodal metastasis, and extracapsular extension. Significance
defined as ANOVA p-value ≤ 0.05 (*), 0.01 (**); minimum correlation coefficient +0.7/−0.7; multiple R2 > 0.5. B, in addition, top ranking peptides
detected across >85% of samples were able to distinguish pN0 and pN+ patients with AUC-ROC > 0.7 calculated using logistic regression and
random forest analysis. Once combined, these peptides performed better as classifiers, achieving an AUC-ROC > 0.85 by binary regression.
AUC-ROC, area under the receiver operating characteristic curve; OSCC, oral squamous carcinoma.
Salivary Peptidome Correlates With Oral Cancer Prognosissurvival (Table 1; supplemental Fig. S2). For instance, upre-
gulation of most cathepsins, CAPN1 and 2, MEP1A, and
MMP25, exhibited a major correlation with poor prognostic
features such as recurrence, perineural invasion, nodal
extracapsular extension, and tumor size. Conversely,
expression of MMP2 and MMP11 was found to be reduced in
cases with advanced tumor stages (T3–T4) and nodal
metastasis (N+).Higher Proteolysis in Saliva May Be Associated With
Diminished Inhibitory Function
Bottom-up proteomics was applied to characterize the
saliva proteome using a second cohort of pN0 and pN+ pa-
tients. This analysis provided valuable information on the
levels of saliva proteases, protease inhibitors, and protein
substrates prone to proteolysis. Most saliva proteins previ-
ously identified through peptide fragments released byMol Cell Proteomics (2021) 20 100004 9
FIG. 5. Cleavage site analysis of differentially abundant peptides and prediction of active proteases. A IceLogo and heat map indicating
position-specific amino acid residues under-represented and over-represented in the putative cleavage site of endogenous peptides. Three N-
and C-terminal residues (depicted by green blocks) were derived from human protein sequences to reconstruct the putative sites cleaved (P1-
P1ʹ) for releasing the differential endogenous peptides (represented by the central blue block). To minimize compositional bias toward the proline
occurrence evidenced on the upper diagram, salivary proline-rich proteins (P04280-PRB1, Q04118-PRB3, P02812-PRB2, P10163-PRB4,
P02814-SMR3B) were excluded in a second analysis (bottom diagram). B, LFQ abundances of differential peptides predicted as substrates of 19
proteases using Proteasix is illustrated as the heat map. Notably, proteolytic products of cathepsins K, L, and S, furin, and calpains are among
the most abundant endogenous peptides. In addition, the levels of cleavage products resulting of cathepsin D (CSTD) activity exhibited higher
intensities in pN+ saliva than in that of pN0.
Salivary Peptidome Correlates With Oral Cancer Prognosisendogenous proteolysis (peptidomics) were also detected
using bottom-up proteomics (Fig. 7A). Interestingly, none of
those exhibited significant changes between the pN0 and pN+
saliva (supplemental Tables S12 and S13), indicating that
changes in the proteolysis balance detected via peptidomics
are off the radar of conventional bottom-up proteomics.
Notably, group variation in saliva proteome was less
remarkable when compared with the peptidome component,
showing only 5 and 24 proteins exclusively detected in pN+
and pN0 groups, respectively (Fig. 7B). Similar to what was
observed in the peptidomic analysis, group-specific differ-
ences at the protein level did not result in the perfect sepa-
ration of pN+ and pN0 patients, as represented by the
hierarchical clustering heat maps of the whole proteome and
differential proteins (Fig. 7, C–D). The volcano plot indicates 18
proteins detected at different levels between the two groups
(ANOVA p-value ≤ 0.05; Fig. 7E). Of these, a subset
comprising lipocalin-1 (LCN1), mucin-7 (MUC7), serum para-
oxonase/arylesterase-1 (PON1), C4b-binding protein alpha10 Mol Cell Proteomics (2021) 20 100004chain (C4BPA), and inter-alpha-trypsin inhibitor heavy chain
H2 (ITIH2) has proved to be useful classifiers of pN0 and pN+
cases by displaying AUC-ROC of logistic regression >80%
(Fig. 8A, supplemetal Table S14). Moreover, among all clini-
copathological features tested, only lymph node metastasis
was found correlated with differentially abundant proteins
(supplemental Fig. S3).
GO analysis of the 18 differentially abundant saliva proteins
revealed the enrichment of terms related to peptidase/endo-
peptidase inhibitor activities (Fig. 8B). More specifically, we
found that 32 protease inhibitors quantified in saliva exhibited
an−0.8× (log2) average reduction inN+patients' saliva,whereas
fetuin A (AHSG), ITIH2, LCN1, and SPINK5 revealed statistically
relevant changes (ANOVA p-value≤ 0.05; Fig. 8C). Interestingly,
in over 40 proteases quantified across the samples, only puro-
mycin-sensitive aminopeptidase (NPEPPS) displayed signifi-
cant changesbetweenpN0andpN+patients (ANOVAp-value≤
0.05), while the average difference between the groups was
closer to the equivalence (average −0.2 × log2; Fig. 8C).
FIG. 6. Functional characterization of predicted proteases implicated in the processing of differential peptides. A, GO enrichment
analysis of the predicted proteases showed a major contribution of lysosomal and vacuole cathepsins. Together, CTSL, CTSK, CTSS, CAPN1,
CAPN2, and CASP6 exhibit cysteine-type peptidase activity, and membrane metalloproteinases (MMP2 and MMP25) are mostly involved in
structural organization of the extracellular matrix via proteolysis. B, network analysis highlighted that predicted cathepsins and membrane
metalloproteases are linked to immunity via Toll-like receptors and antigen presentation. Interaction hub of predicted proteases (squares) and
their top ten interactors (circles); significance threshold p-value was < 0.05. GO, Gene Ontology.
Salivary Peptidome Correlates With Oral Cancer PrognosisThe reduced levels of fetuin A (AHSG) and SPINK5 on N+
saliva was confirmed by a targeted SRM-MS assay using 40
samples of OSCC saliva (N0, n = 14; N+, n = 26). More spe-
cifically, fetuin A proteotypic peptide FSVVYAK revealed a
significant group difference with minor intragroup variations
(Fig. 9A). Of note, a second peptide HTLNQIDEVK was also
monitored for fetuin A but the lack of consistent signal of the
endogenous peptide (light channel) indicated that the analyte
was below the limit of detection (Supplemental Fig. S4). Pro-
tein levels of SPINK5 inferred from the FFQSLDGIMFINK
peptide also suggested lower levels in N+ saliva, although a
high variation among individuals was observed, thus affecting
the verification of statistically significant group differences
(Fig. 9B). Two other peptides selected for SPINK5 quantifi-
cation exhibited low ion response and were not detected in
our SRM analysis (supplemental Fig. S5). Together these data
indicated that reduced levels of protease inhibitors in patients
with lymph node metastasis concur with the accentuated
proteolysis observed in the same group.DISCUSSION
We have developed a peptide-driven workflow able to assist
a molecular-based prognosis of OSCC via peptidomics and
proteomics. The use of saliva has been proposed because it
can be easily collected via noninvasive methodology and it is
in contact with the cancer lesion. The potential of saliva for
providing potential OSCC biomarkers at the protein level using
traditional bottom-up proteomics has been demonstrated by
our group (16, 36). However, saliva is a rich resource of pep-
tides derived from endogenous proteolysis of soluble con-
stituents. Compared with other body fluids with clinical
relevance (e.g., blood, urine, cerebrospinal fluid), low-
molecular-weight peptides account for a higher fraction
(~30%) of total proteinaceous content of saliva (37), what
makes the recovery of small peptides easier and faster than
conventional bottom-up proteomic analyses.
A variety of approaches, including the use of organic sol-
vents (e.g., methanol, MeCN), acids (TFA, HCl), chaotropicMol Cell Proteomics (2021) 20 100004 11
TABLE 1
Correlation between peptidases expression and prognostic features on TCGA clinical data
Protease Prognostic feature p-valuea Expression pattern
CTSD Vital status 0.009 Alive (↑UP); dead (↓DOWN)
Recurrence 0.045 New tumor event detected (↑UP)
CTSS Recurrence 0.044 New tumor event detected (↑UP)
Perineural invasion 0.021 Perineural invasion present (↑UP)
CTSE Pathologic T group 0.026 T3-T4 (↑UP); T1-T2 (↓DOWN)
CTSK Pathologic T group 0.011 T3-T4 (↓DOWN); T1-T2 (↑UP)
CAPN1 Recurrence 0.045 New tumor event detected (↑UP)
CAPN2 Recurrence 0.003 New tumor event detected (↑UP)
Perineural invasion 0.048 Perineural invasion present (↑UP)
Extracapsular extension 0.011 Nodal extracapsular spread (↑UP)
MEP1A Recurrence 0.046 New tumor event detected (↑UP)
Pathologic T group 0.022 T3-T4 (↑UP); T1-T2 (↓DOWN)
MMP2 Pathologic T group 0.006 T3-T4 (↓DOWN); T1-T2 (↑UP)
MMP11 N status 1 0.014 N0 (↑UP); N+ (↓DOWN)
Pathologic T group 0.009 T3-T4 (↓DOWN); T1-T2 (↑UP)
MMP25 Perineural invasion 0.046 Perineural invasion present (↑UP)
TCGA, The Cancer Genome Atlas.
The number of samples for each correlation analysis is available in supplemental Figure S2.
aThe normality of gene expression data was assessed with the Shapiro-Wilk test (α = 0.05). Student's t-test or Welch's test (two group
comparisons) and ANOVA with post hoc Tukey test (>2 groups) were used for parametric data. Nonparametric data were analyzed with Wilcoxon
(two groups) or Kruskal–Wallis (>2 groups) tests. Significance threshold p-value was ≤0.05.
Salivary Peptidome Correlates With Oral Cancer Prognosisagent (urea), ultrafiltration spin devices, and chromatography,
have been shown to be feasible in the extraction of endoge-
nous peptides from complex matrixes (37). Different methods
can bias the extraction toward intrinsic physicochemical fea-
tures of peptides likely affecting the yield and purity or even
leading to the enrichment of structurally modified bioactive
peptides (38). Here we evaluated the efficiency of two
methods of extraction and three chromatography settings in
achieving robust and fast characterization of the saliva pep-
tidome in patients with OSCC. Our extraction methods
explored peptide hydrophobicity upon C18 solid-phase acidic
extraction (HCl-SPE) or separating smaller peptides from
proteins based on molecular ultrafiltration under denaturing
conditions (4 M urea), followed by C18 reversed-phase
desalting (UF-SPE).
The HCl-SPE method demonstrated increased peptidome
coverage and identification rates with no compromise to the
recovery of long peptides, whereas the UF-SPE method
filtered out molecules longer than 27 to 30 residues, likely
explained by the molecular weight cut-off of 3 kDa. Although
membranes with larger pore sizes could be alternatively used,
this might result in a peptidome significantly more contami-
nated with intact low-molecular-weight proteins because a
large proportion (~20%) of the saliva proteome is composed
of proteins <20 kDa (39). Importantly, search engines often
have a maximum peptide length set to ~30 residues as
default, which might affect identification rates of longer pep-
tides and hence should be adjusted accordingly.
The optimized workflow developed in this work was suc-
cessfully applied in the characterization of the salivary pepti-
dome from OSCC patients with or without lymph node12 Mol Cell Proteomics (2021) 20 100004metastasis. Interestingly, the higher number of endogenous
peptides identified exclusively in N+ patients, together with
the increased peptide abundances in the same group, sug-
gests that proteolysis is accentuated in individuals with lymph
node metastasis. In fact, the proteolytic activity in saliva has
been reported to be increased in patients with OSCC
compared with that in healthy individuals or in those with other
benign oral conditions (40).
Of note, our results suggested that proteolysis not only is
accentuated in OSCC but also can be regulated over the
clinical course of the disease. However, we noticed that
quantitative information from either the whole saliva pepti-
dome/proteome or differential peptides/proteins was not able
to perfectly group pN0 and pN+ patients in the hierarchical
clustering. This suggested that other factors might be deter-
minant in the saliva composition, thus affecting the perfor-
mance of the lymph node metastasis status as a single
variable. In fact, at least in the peptidomic analysis, the results
of the correlation analysis reinforced that the quantitative
pattern of differential molecules is also associated with path-
ological features other than lymph node metastasis, such as
perineural invasion and extracapsular extension.
At least five endogenous peptides derived from basic sali-
vary proline-rich protein 1, LCN1, MUC7, serum PON1,
C4BPA, and ITIH2 proteins displayed the ability to better
distinguish pN0 and pN+ patients. Therefore, our results
demonstrated that even with the compositional variation
inherent in the saliva samples, a molecular panel to assess
lymph node metastasis status could be established. Pepti-
domics patterns have been previously reported as capable of
discriminating cancer types, such as breast, prostate, and
FIG. 7. Composition of the saliva proteome from pN0 and pN+ OSCC patients. A, the Venn diagram of saliva proteins exclusive or
commonly identified on peptidomics and proteomics approaches. B, qualitative analysis reveals a major overlap between N0 and N+ saliva
proteomes. C, the heat map of the whole saliva proteome and (D) differentially abundant proteins (ANOVA p-value ≤ 0.05) show no clear
grouping of samples based on a single classifier feature like lymph-node metastasis (N+/N0). Hierarchical clustering was performed using the
Pearson's correlation and Ward's method. E, differential distribution of proteins quantified in pN0 and pN+ samples represented on a volcano
plot. Proteins above the significance threshold (ANOVA p-value ≤ 0.05) are highlighted as red dots.
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FIG. 8. Functional analysis of differentially abundant proteins and ROC curves. A, ROC curves of top-ranking peptides detected across
>85% of samples exhibited AUC-ROC > 0.8, calculated using logistic regression and random forest analysis. B, GO analysis performed by
Enrichr highlights peptidase inhibitory activity and immune-related processes among differentially abundant proteins in saliva. C, quantitative
profiles showed a −0.8-fold (log2) reduction on average abundance of peptidase inhibitors in pN+ saliva. Differences on LCN1, ITIH2, SPINK5,
and AHSG protein levels were statistically significant (ANOVA p-value ≤ 0.05; red bar). On the other hand, average differences in protease levels
were less pronounced (−0.2-fold log2 pN+/pN0) with a single peptidase - NPEPPS, puromycin-sensitive amino peptidase - differentially
abundant (ANOVA p-value ≤ 0.05; red bar). Predicted proteases implicated in the processing of differential endogenous peptides are indicated
by golden bars. AUC-ROC, area under the receiver operating characteristic curve; GO, Gene Ontology.
Salivary Peptidome Correlates With Oral Cancer Prognosisbladder (41). Previous work has shown that breast cancer
plasma peptidomics profiles can be strikingly different be-
tween the patients with early-stage breast cancer and healthy
controls (8), providing its application value besides conven-
tional bottom-up proteomics.
Information regarding proteolytic activity could be antici-
pated by peptidomics analysis and protease predictions. The
remarkable enrichment of proline residues in the sequence
logo highlighted a major contribution of breakdown products
derived from salivary PRP in the saliva of pN+ patients. We
acknowledge, together with histatins and statherins, PRP
fragments as the most abundant products of in-mouth pro-
teolysis (42). PRP peptides are often released upon cleavage
of the Gln-Gly (P1-P1ʹ) motif (43), which was found enriched in
both N- and C- terminals of differential peptides, likely as14 Mol Cell Proteomics (2021) 20 100004result of a glutamine endopeptidase with microbial origin (44).
Importantly, the role of oral microbiota in cancer development
(45) and OSCC aggressiveness (46) has been recently
addressed, reinforcing that oral microbiome can be intimately
linked to molecular aspects of OSCC biology. Noteworthy,
four of five differential peptides with the highest AUC-ROC
(Pep631, Pep163, Pep407, Pep361) were derived from basic
salivary PRPs upon cleavage of the Gln-Gly motif. Notably,
our data suggest that the intrinsic presence and activity of
microbe contaminants in whole saliva provide unique features
relevant for patient classification. However, the collection of
less-contaminated fluids, such as parotid saliva, can also be
considered in OSCC studies.
When PRPs are not considered in the sequence logo
analysis, an additional cleavage specificity highlighted
FIG. 9. Exploratory SRM-MS analysis of protease inhibitor levels in saliva. A, levels of AHSG inferred by FSVVYAK peptide across an
independent 40-patient cohort. AHSG was significantly reduced in N+ saliva, with minor intragroup variation (nested ANOVA, p-value = 0.0215)
and significant difference on group medians (Mann–Whitney, p-value = 0.0019). B, saliva levels of SPINK5 inferred via FFFQSLDGIMFINK
peptide exhibited a higher intragroup variation affecting the confirmation of group differences (Mann–Whitney, p-value > 0.05). AHSG, alpha-2-
HS-glycoprotein (fetuin A); SPINK5, serine protease inhibitor Kazal-type 5; SRM-MS, selected reaction monitoring–mass spectrometry. ANOVA
p-value > 0.05 (ns), ≤0.05 (*), ≤0.01 (**).
Salivary Peptidome Correlates With Oral Cancer Prognosishydrolysis after phenylalanine residues. Cathepsin D is known
to cleave at the C-term of aromatic residues and plays a major
role in the oral cavity proteolysis by promoting the breakdown
of histatins and statherins (47). Interestingly, among all pro-
teases predicted, the cleavage products related to cathepsin
D were notably more abundant in pN+ saliva, suggesting an
increased activity in the saliva of patients with OSCC and
lymph-node metastasis. The relationship between tissue
levels of cathepsin D and invasion, progression, and metas-
tasis has been observed for oral carcinoma (48, 49). Although
it is primarily located within lysosomes in physiological con-
ditions, CTSD overexpression in cancer cells results in hy-
persecretion of this protease (50), which might eventually leadto its increased activity in saliva. Similarly, other predicted
cathepsins also exhibit vital intracellular roles. As anticipated
by the network analysis, the cysteine cathepsins B, K, and L
are linked to immune-related processes via Toll-like receptors
and human leukocyte antigen associated with major histo-
compatibility complex class II (MHC class II), thus highlighting
that imbalances in their catalytic activity have the potential to
impair immune responses to cancer (51).
Expression data available in public repositories suggested
that increased tissue expression of calpains 1 and 2 and
MMP11 decrease overall patient survival and higher levels of
meprin 1A can be associated with recurrence and tumor size.
However, although mRNA levels in tumor tissues suggest aMol Cell Proteomics (2021) 20 100004 15
Salivary Peptidome Correlates With Oral Cancer Prognosisregulation on proteolytic processes via peptidase levels, this
may not be entirely reflected in the saliva peptidome for many
reasons. For instance, our results support the finding that the
saliva peptidome is a pool of products generated by pepti-
dases whose origin is in the oral microflora (e.g., bacteria
glutamine protease), host salivary glands, immune cells (e.g.,
proteasix predicted granzyme A, GZMA), and tumor cells.
Therefore, the peptidomic-driven strategy might constitute a
singular approach to assess the outcome of peptidase activity
in saliva, regardless of the expression patterns observed in
adjacent tissues/cells.
Remarkably, enzymatic activity of peptidases can be regu-
lated by multiple mechanisms including their own expression
levels, structural modification (e.g., zymogen processing and
post-translational modifications), and changes in inhibitory
control. As a matter of fact, our parallel bottom-up proteomic
analysis showed only small differences in the levels of proteases
quantified in saliva, whereas protease inhibitors exhibited an
important reduction in pN+ samples. This led to the assumption
that modulation of inhibitory functions may in great part induce
the changes in the saliva peptidome in more advanced cases of
OSCC diagnosed with lymph-node metastasis.
The four protease inhibitors significantly reduced in N+
saliva, namely, fetuin A (AHSG), ITIH2, LCN1, and SPINK5,
display inhibitory activity over a wide range of serine and
cysteine proteases. SPINK5 protein possesses a major
inhibitory activity on kallikrein 5, which has been described
with increased activity in OSCC saliva (40), whereas fetuin A
(AHSG) displays a broad-range inhibitory activity including
meprin zinc metalloproteinases and trypsin (52). Noteworthy,
fetuin A has been proposed as a marker for metastasis in
prostate cancer (53, 54).
The lower levels of fetuinA in theN+saliva couldbeconfirmed
by SRM-MS analysis on a larger and independent cohort of
patients with OSCC. These new findings indicated a similar
tendency with our previous results on the cysteine–protease
inhibitor, cystatin-B, that presented reduced levels in
neoplastic islands from the invasive tumor front and also in the
saliva of N+ OSCC patients compared with that in N0 OSCC
patients (19). Of note, quantification of SPINK5 protein via tar-
geted proteomics remains inconclusive as the only high-
responding peptide detected exhibited suboptimal quanto-
typic qualities (i.e., presence of methionine residue), which
might have contributed to the higher variation observed. In
addition, poor detection of the two additional SPINK5 peptides
provides evidence that the selection of peptides for targeted
proteomics remains challenging. In this context, the use of
computational tools able to predict peptides with the highest
ion responsemight increase the success rate (55, 56). Although
the inference of protein abundances using a single peptidemay
not be ideal, we observed that label-free quantification using
data-dependent acquisition and label-based using SRM from
two independent patient cohorts corroborated the slightly16 Mol Cell Proteomics (2021) 20 100004reduced levels of fetuin A and SPINK5 protease inhibitors in
OSCC N+ saliva.
Taken together, the strategy we presented here constitutes
a multifaceted approach for comprehensive characterization
of proteolytic events in OSCC via peptidomics, bottom-up
proteomics, and in silico analysis of cleavage sites. The
entire quantitative workflow, encompassing optimized sample
preparation, LC-MS/MS acquisition, and data analysis, pro-
vided a basis for future peptidomics applications in biological
and translational studies. We demonstrated that the salivary
peptidome is differentially regulated in patients with OSCC
and nodal metastasis as a result of increased activity of pro-
teases with oral microflora or host cell origin. This accentuated
proteolysis concurs with a reduction of protease inhibitors in
the saliva proteome. Specific features of the proteolytic
network such as the peptide fragments of basic salivary pro-
line-rich protein 1 and the proteins LCN1, MUC7, PON1,
C4BPA, ITIH2, and AHSG have proved useful in distinguishing
patients with cervical lymph-node metastasis. Therefore, our
results ultimately provided a panel of analytes with prognostic
utility that might assist subgrouping patients with poor prog-
nosis requiring tailored therapeutic interventions.DATA AVAILABILITY
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51. Jakoš, T., Pišlar, A., Jewett, A., and Kos, J. (2019) Cysteine cathepsins in
tumor-associated immune cells. Front. Immunol. 10, 2037
52. Hedrich, J., Lottaz, D., Meyer, K., Yiallouros, I., Jahnen-Dechent, W.,
Stöcker, W., and Becker-Pauly, C. (2010) Fetuin-A and cystatin C are
endogenous inhibitors of human meprin metalloproteases. Biochemistry
49, 8599–8607
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